ClinicalTrials.gg
CompletedNCT01518855Updated Jan 26, 2012

Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension

A Phase 4 interventional study of Nifedipine (Adalat, BAYA1040) and Amlodipine (Norvasc) in Hypertension, sponsored by Bayer. Completed at 4 sites in Japan. Open to participants aged 20 Years to 79 Years. Per ClinicalTrials.gov, last updated 2012-01-26.

Sponsored by Bayer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
514
Allocation
Randomized
Ages
20 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 29 studies testing nifedipine in Hypertension — 3 open to participants now, 3 under way, 1 of them phase 3. Nifedipine · Hypertension.

Enrollment
2nd of 29
514 · median 72
Started
2004
the only one that year
Phase 4
12 of 29
1 open now
Registered
14th of 29
by date
Lead sponsor
11 of 29
Bayer

Among the 29 studies testing nifedipine in Hypertension, this one is the 2nd largest by enrollment, is the only one that started in 2004, is one of 12 in phase 4, and was the 14th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

3 of the 29 studies testing nifedipine in Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nifedipine

Nifedipine: first FDA approval 1981 (PROCARDIA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing nifedipine in Hypertension, or all of them as a file.
02

Study summary

The primary objective of this study is to investigate incremental cost effectiveness of Nifedipine CR and Amlodipine in combination therapy with Valsartan for the treatment of essential hypertensive patients.

To investigate incremental cost effectiveness, primary variables are mean treatment cost and achievement rate to target blood pressure level at the end of double-blind treatment period.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
20 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Untreated patients or patients with previous treatment by antihypertensive agents whose blood pressure at sitting position at the time of the entry (Visit 1) is:

  • SBP>/=160mmHg or DBP>/=100mmHg for untreated patients (SBP Systolic blood pressure, DBP Diastolic blood pressure)
  • SBP>/=150mmHg or DBP>/=95mmHg for patients with previous treatment by antihypertensive agents

Exclusion criteria

Exclusion Criteria:

  • Patients whose blood pressure on either day of Visit 1 or 2 is: SBP > 200mmHg or DBP > 120mmHg.
  • Patients with secondary hypertension or hypertensive emergency such as malignant hypertension.
  • Patients with a history of cardiovascular or cerebrovascular ischemic event (stroke, , myocardial infarction or unstable angina) within six months prior to the study.
  • Patients with a history of intracranial or subarachnoid hemorrhage within six months prior to the study.
  • Patients with uncontrolled diabetes ( >/=8%)
  • Patients with bradycardia or tachycardia (\<50 bpm, >/=100 bpm), arrhythmia such as atrioventricular block (second and third degree), sinoatrial block or atrial fibrillation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
514 participants (actual)

Study arms

  • Experimental
    Arm 1

    Adalat CR 20-40mg od + Diovan 40-80mg od

    Drug: Nifedipine (Adalat, BAYA1040) · Drug: Diovan

  • Active comparator
    Arm 2

    Norvasc 2.5-5mg od + Diovan 40-80mg od

    Drug: Amlodipine (Norvasc) · Drug: Diovan

06

What researchers measure

Primary outcomes

  1. Mean treatment cost* for 16-week of double-blind treatment period

    \* Including treatment cost for the drug related AEs. The sponsor will calculate the cost based on the tariff of health insurance scores.

    Time frame: 16 weeks

  2. Proportion of participants** achieving target blood pressure at the end of double-blind treatment period

    \*\*For subjects aged under 60 years: SBP\<130mmHg and DBP\<85mmHg, for subjects aged 60 years or over: SBP\<140mmHg and DBP\<90mmHg (SBP Systolic blood pressure, DBP Diastolic blood pressure)

    Time frame: at week 16

Secondary outcomes

  1. Treatment cost per subject to achieve the target blood pressure (Total costs for the double-blind treatment period / Number of patients who achieve the target blood pressure at the end of double-blind treatment period)

    Time frame: 16 weeks

  2. The change in blood pressure (SBP and DBP) from the baseline (end of pretreatment period) .

    Time frame: baseline to week 16

  3. Proportion of participants for each age group to target blood pressure level

    Time frame: at week 16

  4. Incidence of treatment-emergent drug-related adverse events

    Time frame: 16 weeks

  5. Safety variables will be summarized using descriptive statistics based on adverse events collections

    Time frame: 16 weeks

07

Study locations

4 sites
  • Sapporo, Hokkaido 060-0003, Japan
  • Setagaya-ku, Tokyo 158-0097, Japan
  • Shinjuku-ku, Tokyo 163-6003, Japan
  • Hiroshima, 733-0011, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004, a primary completion of Apr 2005 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2012
First posted
Jan 26, 2012
Start
Mar 2004
Primary completionActual
Apr 2005
CompletionActual
Apr 2005
Last update
Jan 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01518855
Lead sponsor
Bayer
First posted
Jan 26, 2012
Start date
Mar 2004
Primary completion
Apr 2005
Completion
Apr 2005
Last update
Jan 26, 2012

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nifedipine

Start the discussion